Analysts Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Target Price at $94.57

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $94.57.

Several equities research analysts recently issued reports on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Cantor Fitzgerald started coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. Barrington Research increased their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, JMP Securities increased their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors have recently made changes to their positions in the stock. NBC Securities Inc. increased its stake in LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares during the period. GAMMA Investing LLC increased its position in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares during the period. West Oak Capital LLC acquired a new position in LeMaitre Vascular in the second quarter valued at about $58,000. USA Financial Formulas bought a new stake in LeMaitre Vascular during the third quarter worth about $60,000. Finally, nVerses Capital LLC grew its stake in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $106.99 on Thursday. LeMaitre Vascular has a 52-week low of $51.70 and a 52-week high of $109.58. The company has a market cap of $2.41 billion, a P/E ratio of 58.46, a P/E/G ratio of 2.59 and a beta of 0.89. The stock’s 50-day simple moving average is $95.52 and its 200 day simple moving average is $87.96.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. During the same quarter in the prior year, the business posted $0.33 EPS. The business’s revenue was up 15.6% compared to the same quarter last year. As a group, equities analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be given a $0.16 dividend. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.60%. LeMaitre Vascular’s payout ratio is presently 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.